Holen Sie sich die Stockscreener-App
1.76
4.35%
-0.08
Schlusskurs vom Vortag:
$1.84
Offen:
$1.83
24-Stunden-Volumen:
623.04K
Relative Volume:
0.37
Marktkapitalisierung:
$100.85M
Einnahmen:
$70.00M
Nettoeinkommen (Verlust:
$-43.21M
KGV:
-2.3222
EPS:
-0.7579
Netto-Cashflow:
$-34.03M
1W Leistung:
-1.68%
1M Leistung:
-5.38%
6M Leistung:
-32.57%
1J Leistung:
-43.59%
1-Tages-Spanne:
$1.75
$1.83
1-Wochen-Bereich:
$1.75
$1.895
52-Wochen-Spanne:
$1.60
$4.94
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
Firmenname
Black Diamond Therapeutics Inc
Sektor
Branche
Telefon
617-417-5868
Adresse
245 FIRST STREET, 18TH FLOOR, CAMBRIDGE, MA
Compare BDTX vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BDTX
Black Diamond Therapeutics Inc
|
1.76 | 100.85M | 70.00M | -43.21M | -34.03M | -0.7579 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-11-18 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-10-16 | Fortgesetzt | Stifel | Buy |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2025-07-01 | Fortgesetzt | Raymond James | Outperform |
| 2024-07-31 | Eingeleitet | Raymond James | Outperform |
| 2023-07-14 | Eingeleitet | Piper Sandler | Overweight |
| 2023-06-30 | Hochstufung | Stifel | Hold → Buy |
| 2023-06-28 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-06-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-03-29 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-03-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-09-30 | Eingeleitet | Stifel | Hold |
| 2021-01-07 | Eingeleitet | Wedbush | Outperform |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-24 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-02-24 | Eingeleitet | Cowen | Outperform |
| 2020-02-24 | Eingeleitet | JP Morgan | Overweight |
| 2020-02-24 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Black Diamond Therapeutics Inc Aktie (BDTX) Neueste Nachrichten
BDTX|Black Diamond Therapeutics Inc|Price:1.760|Chg%:-0.080 - TradingKey
BLACK DIAMOND THERAPEUTICS I (BDTX) Stock Price & Overview - ChartMill
Black Diamond Therapeutics (BDTX) 24th Annual Needham Virtual Healthcare Conference summary - Quartr
Black Diamond Therapeutics (BDTX) Edges Higher Amid Key Support TestSeasonality Effect - dars.gov.et
BDTX Q1 2026 Earnings: Narrowed Loss Beats Estimates as Development Progress ContinuesConsensus Beat Rate - dars.gov.et
T. Rowe Price (BDTX) lists 4.03M shares, 7.0% stake in amendment - Stock Titan
Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside (NASDAQ:BDTX) - Seeking Alpha
BDTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
BDTX SEC FilingsBlack Diamond Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Behbahani Ali - Moomoo
Black Diamond Therapeutics touts Silevertinib lung cancer data, eyes FDA path - MSN
Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Raman Prakash - Moomoo
Black Diamond Therapeutics 2026 Annual Stockholder Meeting Results and Voting Outcomes - Minichart
Form 4 Black Diamond Therapeutics Inc For: 29 June By Investing.com - Investing.com Nigeria
[Form 4] Black Diamond Therapeutics, Inc. Insider Trading Activity - Stock Titan
Black Diamond (BDTX) director awarded 40,000 stock options at $1.71 - Stock Titan
Black Diamond Therapeutics (BDTX) director awarded 40,000 stock options at $1.71 - Stock Titan
Director Garry Menzel granted 40,000 BDTX stock options at $1.71 strike - Stock Titan
Black Diamond (NASDAQ: BDTX) director receives 40,000 stock options at $1.71 - Stock Titan
Black Diamond Therapeutics (BDTX) awards 40,000-share option grant - Stock Titan
Black Diamond Therapeutics (BDTX) 2026 meeting backs directors, auditor and annual say-on-pay - Stock Titan
Black Diamond Therapeutics, Inc.(NasdaqGS: BDTX) added to Russell 2000 Index - marketscreener.com
Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 2000 Value Benchmark - marketscreener.com
Black Diamond Therapeutics, Inc.(NasdaqGS: BDTX) added to Russell 3000E Index - marketscreener.com
Enterprise value to EBITDA forward of Black Diamond Therapeutics, Inc. – NASDAQ:BDTX - TradingView
Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell Small Cap Completeness Index - marketscreener.com
Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 2500 Value Benchmark - marketscreener.com
Black Diamond Therapeutics (BDTX) AGM 2026 Summary - Quartr
Price to sales forward of Black Diamond Therapeutics, Inc. – NASDAQ:BDTX - TradingView
Price to book forward of Black Diamond Therapeutics, Inc. – BOATS:BDTX - TradingView
Black Diamond Therapeutics, Inc. Actuals & Estimates (NASDAQ:BDTX) - TradingView
Enterprise value to EBIT forward of Black Diamond Therapeutics, Inc. – NASDAQ:BDTX - TradingView
Price to earnings forward of Black Diamond Therapeutics, Inc. – BOATS:BDTX - TradingView
Price to sales forward of Black Diamond Therapeutics, Inc. – BOATS:BDTX - TradingView
Enterprise value to revenue forward of Black Diamond Therapeutics, Inc. – BOATS:BDTX - TradingView
BDTX shares gain 11% in a week: Here's what you should know - MSN
BDTX Forecast — Price Target — Prediction for 2027 - TradingView
Black Diamond Therapeutics (BDTX) Rallies 3.11%: Testing Key Resistance at $1.74Moving Average Ribbon - DonanımHaber
Form 4 Black Diamond Therapeutics Inc For: 22 June By Investing.com - Investing.com Nigeria
Ali Behbahani of Black Diamond (NASDAQ: BDTX) receives 8,961-share award - Stock Titan
Black Diamond Therapeutics Inc (BDTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Black Diamond Therapeutics Inc (BDTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Black Diamond Therapeutics Inc (BDTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Black Diamond Therapeutics Inc - TradingKey
Black Diamond Therapeutics Inc (BDTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Black Diamond Therapeutics Inc (BDTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Black Diamond Therapeutics Inc (BDTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Black Diamond Therapeutics Inc (BDTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Black Diamond Therapeutics Inc (BDTX) Institutional Confidence - TradingKey
Black Diamond Therapeutics (BDTX) Holds Near Support Amid Modest DeclineEqual Weight ETF - newsline.com
Black Diamond Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss as Pipeline AdvancesEarnings Recovery Stocks - newsline.com
Finanzdaten der Black Diamond Therapeutics Inc-Aktie (BDTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.46%
0.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):